Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 155 Show results per page	View Search Criteria \| Help With Results


1.		Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Biomarker/Laboratory analysis, Diagnostic, Tissue collection/Repository, Treatment				Active				18 to 75				Other				2005-401 NCT00327093

Last Modified: 2/27/2008 First Published: 7/24/2007


2.		Phase II/III Randomized Study of Chemoradiotherapy Comprising Cisplatin, Capecitabine, and Radiotherapy With or Without Cetuximab in Patients With Carcinoma of the Esophagus

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Other				WCTU-SCOPE-1 EU-20739, EUDRACT-2006-002241-37, ISRCTN47718479, CTA-17853/0202/001-0001, NCT00509561

Last Modified: 9/19/2008 First Published: 2/20/2004


3.		Phase III Randomized Study of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients with Stage III Colon Cancer (Note: All Treatment Arms Containing Irinotecan Closed to Accrual as of 6/1/2005)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				NCCTG-N0147 ECOG-N0147, N0147, NCT00079274


4.		Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				CP02-0452 NCT00095199

Last Modified: 4/4/2008 First Published: 12/9/2005


5.		Phase III Randomized Study of Adjuvant Combination Chemotherapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil With Versus Without Cetuximab in Patients With Completely Resected Stage III Colon Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 74				Other, Pharmaceutical / Industry				FFCD-PETACC-8 EU-20547, EUDRACT-2005-003463-23, PETACC-8, MERCK-FFCD-PETACC-8, NCT00265811

Last Modified: 9/19/2008 First Published: 12/9/2005


6.		Phase III Randomized Study of Concurrent Accelerated Fractionated Radiotherapy and Cisplatin With Versus Without Cetuximab in Patients With Stage III or IV Squamous Cell Carcinoma of the Oropharynx, Hypopharynx, or Larynx

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				RTOG-0522 RTOG-0522, NCT00265941

Last Modified: 9/19/2008 First Published: 4/8/2008


7.		Phase III Randomized Study of Chemoradiotherapy Comprising Paclitaxel, Cisplatin, and Radiotherapy With Versus Without Cetuximab in Patients With Locally Advanced Esophageal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				RTOG-0436 RTOG-0436, NCT00655876

Last Modified: 8/12/2008 First Published: 5/23/2007


8.		Phase III Randomized Study of Neoadjuvant and Adjuvant Combination Chemotherapy With Versus Without Cetuximab in Patients With Resectable Colorectal Liver Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				USCTU-4351 EPOC, USCTU-EPOC, EUDRACT-2006-003121-82, ISRCTN22944367, EU-20732, NCT00482222

Last Modified: 5/20/2008 First Published: 3/19/2008


9.		Phase III Randomized Study of Cetuximab With Versus Without Brivanib Alaninate in Patients With Metastatic Colorectal Carcinoma Previously Treated With Combination Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				CAN-NCIC-CO20 CO20, CAN-NCIC-CA182009, NCT00640471


10.		Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-Gastric Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				EMR 200048-052 NCT00678535

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute